Drug:
Reaction: ACCIDENTAL EXPOSURE TO PRODUCT
20250101 - 20251231
No. 201 - 300
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 201 | 25114565 |
US |
73 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 202 | 25114711 |
US |
84 | 2 |
Unresponsive to stimuli, Apnoeic attack, Accidental exposure to product, Device malfunction, |
||||
PROPOFOL, |
||||
| 203 | 25114881 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 204 | 25114975 |
US |
2 | |
Accidental exposure to product, |
||||
TRAVOPROST, |
||||
| 205 | 25115143 |
US |
2 | |
Device defective, Accidental exposure to product, Drug dose omission by device, Inappropriate schedule of product administration, |
||||
SECUKINUMAB, CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, |
||||
| 206 | 25115145 |
US |
2 | |
Device leakage, Accidental exposure to product, Needle issue, Drug dose omission by device, |
||||
SECUKINUMAB, LEVOTHYROXINE, CITALOPRAM, |
||||
| 207 | 25109346 |
US |
68 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 208 | 25109456 |
US |
55 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 209 | 25109481 |
US |
1 | |
Exposure via skin contact, Product dose omission issue, Accidental exposure to product, Product use in unapproved indication, Product complaint, |
||||
MEPOLIZUMAB, |
||||
| 210 | 25109487 |
US |
11 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 211 | 25109587 |
US |
63 | |
Hepatic enzyme increased, Device difficult to use, Accidental exposure to product, Therapy interrupted, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 212 | 25109624 |
US |
||
Nausea, Taste disorder, Hypoaesthesia oral, Eye disorder, Accidental exposure to product, Occupational exposure to product, |
||||
EVOLOCUMAB, |
||||
| 213 | 25109636 |
US |
71 | 2 |
Device difficult to use, Accidental exposure to product, Therapy interrupted, Incorrect disposal of product, |
||||
EVOLOCUMAB, |
||||
| 214 | 25109741 |
GB |
59 | 2 |
Device issue, Accidental exposure to product, Device deployment issue, |
||||
GOLIMUMAB, GOLIMUMAB, |
||||
| 215 | 25107748 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 216 | 25107751 |
US |
||
Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 217 | 25107752 |
US |
79 | 1 |
Pruritus, Product dose omission issue, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, RITUXIMAB, PRAVASTATIN SODIUM, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, FINASTERIDE, PRASTERONE, ICOSAPENT ETHYL, ALENDRONATE SODIUM, THIAMINE HYDROCHLORIDE, RIBOFLAVIN 5 PHOSPHATE SODIUM, DEXPANTHENOL AND NIACINAMIDE, ERGOCALCIFEROL, ROSUVASTATIN CALCIUM, TESTOSTERONE CYPIONATE, ACYCLOVIR, MONTELUKAST SODIUM, MONTELUKAST, THYROID, PORCINE, ALENDRONATE SODIUM, |
||||
| 218 | 25107764 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 219 | 25107767 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 220 | 25107770 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 221 | 25107774 |
US |
67 | 1 |
Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 222 | 25107783 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 223 | 25107784 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 224 | 25107796 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 225 | 25107816 |
US |
7 | 1 |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 226 | 25107829 |
US |
1 | |
Accidental exposure to product, Exposure via eye contact, |
||||
DUPILUMAB, |
||||
| 227 | 25107863 |
US |
52 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 228 | 25107884 |
US |
68 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 229 | 25107897 |
US |
51 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 230 | 25107945 |
US |
67 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE AND LIXISENATIDE, |
||||
| 231 | 25107949 |
US |
71 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 232 | 25108115 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 233 | 25108127 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 234 | 25108143 |
US |
25 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 235 | 25108144 |
US |
10 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 236 | 25108150 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 237 | 25108157 |
US |
61 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 238 | 25108167 |
US |
29 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 239 | 25108195 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 240 | 25108220 |
US |
61 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 241 | 25108255 |
US |
36 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 242 | 25108379 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 243 | 25108704 |
US |
27 | 2 |
Drug dose omission by device, Accidental exposure to product, Device malfunction, |
||||
ADALIMUMAB-ADAZ, ADALIMUMAB-ADAZ, ADALIMUMAB-ADAZ, ADALIMUMAB-ADAZ, |
||||
| 244 | 25108766 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 245 | 25108792 |
US |
31 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 246 | 25108879 |
US |
2 | |
Product dispensing error, Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 247 | 25108956 |
US |
80 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 248 | 25109000 |
US |
71 | 2 |
Accidental exposure to product, |
||||
FREMANEZUMAB-VFRM, |
||||
| 249 | 25102486 |
US |
44 | 1 |
Accidental exposure to product, No adverse event, Wrong technique in product usage process, |
||||
OMALIZUMAB, OMALIZUMAB, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, |
||||
| 250 | 25102532 |
US |
51 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 251 | 25102556 |
US |
42 | 2 |
Device issue, Accidental exposure to product, Injury associated with device, Drug dose omission by device, |
||||
OFATUMUMAB, |
||||
| 252 | 25102782 |
US |
62 | 2 |
Blood cholesterol increased, Accidental exposure to product, Drug dose omission by device, Device difficult to use, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 253 | 25102785 |
US |
50 | 2 |
Headache, Accidental exposure to product, Incorrect dose administered by device, Wrong technique in product usage process, Device difficult to use, |
||||
ERENUMAB-AOOE, |
||||
| 254 | 25103294 |
US |
1 | |
Device issue, Product leakage, Accidental exposure to product, Product dose omission issue, |
||||
SECUKINUMAB, |
||||
| 255 | 25103309 |
CH |
2 | |
Device defective, Accidental exposure to product, Device deployment issue, |
||||
GOLIMUMAB, GOLIMUMAB, |
||||
| 256 | 25103411 |
US |
64 | 1 |
Accidental exposure to product, Device leakage, |
||||
PEGFILGRASTIM, |
||||
| 257 | 25103658 |
US |
2 | |
Extra dose administered, Accidental exposure to product, No adverse event, |
||||
FEXOFENADINE HYDROCHLORIDE, |
||||
| 258 | 25103898 |
US |
2 | |
Needle issue, Accidental exposure to product, Device leakage, Product dose omission issue, |
||||
OFATUMUMAB, |
||||
| 259 | 25104306 |
US |
20 | 2 |
Accidental exposure to product, Drug dose omission by device, Depression, Dizziness, Sleep disorder, Stress, Vomiting, Depressed mood, Wrong technique in product usage process, Sleep deficit, |
||||
ERENUMAB-AOOE, PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE, |
||||
| 260 | 25104408 |
US |
78 | 2 |
Eye pain, Accidental exposure to product, |
||||
POTASSIUM NITRATE AND SODIUM FLUORIDE, POTASSIUM NITRATE, SODIUM FLUORIDE, STANNOUS FLUORIDE, POTASSIUM NITRATE, |
||||
| 261 | 25104488 |
US |
2 | |
Wrong technique in device usage process, Accidental exposure to product, Product dose omission issue, |
||||
GUSELKUMAB, |
||||
| 262 | 25105275 |
US |
50 | 2 |
Device malfunction, Device issue, Accidental exposure to product, Product dose omission issue, Drug delivery system malfunction, Injury associated with device, |
||||
GUSELKUMAB, |
||||
| 263 | 25105685 |
US |
2 | |
Accidental exposure to product, Wrong product administered, Lethargy, Nausea, |
||||
BUPRENORPHINE, |
||||
| 264 | 25106153 |
CO |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
SOMATROPIN, |
||||
| 265 | 25106316 |
US |
44 | 1 |
Device difficult to use, Accidental exposure to product, Wrong technique in product usage process, Drug dose omission by device, Injection site haemorrhage, Incorrect disposal of product, |
||||
ERENUMAB-AOOE, |
||||
| 266 | 25106513 |
CO |
39 | 2 |
Pyelocaliectasis, Dysgeusia, Application site discolouration, Papule, Skin exfoliation, Pain of skin, Pain, Somnolence, Treatment noncompliance, Therapy interrupted, Accidental exposure to product, Wrong technique in product usage process, Arthropathy, Osteoarthritis, Erythema, Pruritus, |
||||
MECHLORETHAMINE HYDROCHLORIDE, MECHLORETHAMINE HYDROCHLORIDE, MECHLORETHAMINE HYDROCHLORIDE, ESZOPICLONE, DULOXETINE HYDROCHLORIDE, DULOXETIN HYDROCHLORIDE, DULOXETINE, ESCITALOPRAM OXALATE, ESCITALOPRAM, QUETIAPINE FUMARATE, QUETIAPINE, SERTRALINE HYDROCHLORIDE, |
||||
| 267 | 25106687 |
US |
64 | 2 |
Device leakage, Accidental exposure to product, Wrong technique in product usage process, |
||||
PEGFILGRASTIM, PEGFILGRASTIM, |
||||
| 268 | 25097279 |
US |
13 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 269 | 25097424 |
US |
74 | 2 |
Injury associated with device, Wrong technique in product usage process, Device use error, Accidental exposure to product, Drug dose omission by device, Injection site haemorrhage, |
||||
EVOLOCUMAB, |
||||
| 270 | 25097504 |
US |
85 | 1 |
Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 271 | 25097506 |
US |
32 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 272 | 25097614 |
US |
11 | 2 |
Product dose omission issue, Accidental exposure to product, Device issue, No adverse event, Product quality issue, Needle issue, Off label use, |
||||
OMALIZUMAB, OMALIZUMAB, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, ALBUTEROL SULFATE, |
||||
| 273 | 25097766 |
US |
46 | 1 |
Injection site vesicles, Injection site mass, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 274 | 25097782 |
US |
8 | 1 |
Eczema, Product dose omission issue, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 275 | 25097885 |
US |
56 | 2 |
Eczema, Skin swelling, Skin fissures, Skin haemorrhage, Pain, Oral herpes, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 276 | 25098165 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 277 | 25098221 |
US |
38 | 2 |
Injection site pain, Device difficult to use, Wrong technique in product usage process, Accidental exposure to product, Drug dose omission by device, |
||||
ERENUMAB-AOOE, |
||||
| 278 | 25098336 |
US |
2 | |
Nephrolithiasis, Device malfunction, Dermatitis allergic, Incorrect dose administered by device, Injection site pain, Muscle tightness, Accidental exposure to product, Burning sensation, Typical aura without headache, |
||||
FREMANEZUMAB-VFRM, |
||||
| 279 | 25098529 |
US |
54 | 2 |
Product dose omission issue, Accidental exposure to product, Device malfunction, |
||||
SECUKINUMAB, |
||||
| 280 | 25098693 |
US |
2 | |
Accidental exposure to product, |
||||
FENTANYL, |
||||
| 281 | 25099100 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 282 | 25099151 |
US |
35 | 2 |
Device failure, Accidental exposure to product, Product dose omission issue, Product leakage, |
||||
GUSELKUMAB, |
||||
| 283 | 25099369 |
US |
||
Accidental exposure to product, Extra dose administered, |
||||
LORATADINE, LORATADINE ORAL, |
||||
| 284 | 25099562 |
US |
42 | 2 |
Dry skin, Pruritus, Drug dose omission by device, Device operational issue, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 285 | 25099563 |
US |
71 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 286 | 25099599 |
FR |
32 | 2 |
Condition aggravated, Product leakage, Product dose omission issue, Accidental exposure to product, |
||||
GUSELKUMAB, |
||||
| 287 | 25099640 |
US |
84 | 2 |
Unresponsive to stimuli, Apnoeic attack, Accidental exposure to product, Device malfunction, |
||||
PROPOFOL, |
||||
| 288 | 25099906 |
US |
2 | |
Haemorrhage, Injury associated with device, Accidental exposure to product, |
||||
AFLIBERCEPT, |
||||
| 289 | 25099907 |
US |
2 | |
Haemorrhage, Injury associated with device, Accidental exposure to product, |
||||
AFLIBERCEPT, |
||||
| 290 | 25100700 |
US |
57 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, INSULIN LISPRO, |
||||
| 291 | 25100701 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 292 | 25100889 |
US |
70 | 2 |
Pruritus, Incorrect dose administered, Product dose omission issue, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 293 | 25101159 |
US |
||
Accidental exposure to product, Device difficult to use, Incorrect dose administered by device, Product substitution issue, Device issue, |
||||
TESTOSTERONE, TESTOSTERONE,, TESTOSTERONE, TESTOSTERONE,, TESTOSTERONE, TESTOSTERONE,, |
||||
| 294 | 25101261 |
US |
44 | |
Rheumatoid arthritis, Injection site haemorrhage, Device difficult to use, Wrong technique in product usage process, Accidental exposure to product, |
||||
ETANERCEPT, |
||||
| 295 | 25101580 |
US |
2 | |
Drug dose omission by device, Accidental exposure to product, Device leakage, |
||||
SECUKINUMAB, |
||||
| 296 | 25101816 |
US |
||
Device deployment issue, Accidental exposure to product, |
||||
GUSELKUMAB, |
||||
| 297 | 25101894 |
US |
||
Shoulder operation, Fatigue, Exposure via skin contact, Wrong technique in device usage process, Accidental exposure to product, |
||||
MEPOLIZUMAB, |
||||
| 298 | 25101935 |
US |
1 | |
Needle issue, Accidental exposure to product, Product leakage, |
||||
SECUKINUMAB, |
||||
| 299 | 25092104 |
US |
68 | 1 |
Device difficult to use, Drug dose omission by device, Accidental exposure to product, Nasopharyngitis, Illness, |
||||
EVOLOCUMAB, |
||||
| 300 | 25092138 |
US |
69 | 2 |
Injury associated with device, Accidental exposure to product, Wrong technique in product usage process, |
||||
EVOLOCUMAB, EVOLOCUMAB, NITROGLYCERIN, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, LOSARTAN, LEVOTHYROXINE, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28